Dr. Martens Plc (DE:3U2)
FRANKFURT:3U2
3U2 Stock Chart & Stats
€0.72
-€0.09(-9.68%)
At close: 4:00 PM EST
€0.72
-€0.09(-9.68%)
Day’s Range― - ―
52-Week Range€0.66 - €1.11
Previous CloseN/A
Volume0.00
Average Volume (3M)406.00
Market Cap
€789.64M
Enterprise Value€919.33M
Total Cash (Recent Filing)€180.30M
Total Debt (Recent Filing)€391.40M
Price to Earnings (P/E)28.6
Beta0.96
Next Earnings
Nov 19, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding967,943,540
10 Day Avg. Volume2
30 Day Avg. Volume406
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.68
Price to Sales (P/S)0.79
P/FCF Ratio5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.14Price Target Upside58.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€9.11M
Bulls Say, Bears Say
Bulls Say
Full-price DTC MixImproving full-price DTC sales signals strengthening pricing power and better revenue quality. Over the medium term this reduces reliance on markdowns, supports higher gross margins per unit, and helps preserve brand equity while enabling more predictable cashflows and margin sustainability.
Operating Profit RecoveryThe swing to operating profitability reflects effective cost control and improved commercial execution. Sustained operating margin improvement increases internal funding for growth, supports deleveraging, and demonstrates management can restore core profitability even with slower top-line trends.
Solid Cash GenerationConsistent free cash flow provides durable financial flexibility to service debt, fund store and DTC investments, and return capital. Strong cash conversion reduces refinancing risk and permits strategic initiatives even if revenue growth remains muted over the next several quarters.
Bears Say
Multi-year Revenue DeclineA persistent top-line decline signals structural demand or market-share issues. Over time shrinking revenue constrains operating leverage, limits reinvestment capacity, and makes margin recovery and profitable scale harder, increasing execution risk for a brand reliant on DTC and wholesale reach.
Margin Compression Vs. Prior PeaksMaterial margin erosion from prior peaks reduces long-term return potential and sensitivity to cost shocks. Even with recent improvement, lower gross and net margins limit the firm's ability to absorb input cost inflation or reinvestment without depressing profitability or requiring sustained mix improvement.
EMEA DTC Weakness & Product/tariff HeadwindsRegional DTC softness, ongoing product-segment issues, and tariff costs represent structural headwinds to both growth and margins. Addressing these requires product redesign, marketing or channel shifts and tariff mitigation—each multi-quarter initiatives that add execution risk and cost pressure.
Dr. Martens Plc News
3U2 FAQ
What was Dr. Martens Plc’s price range in the past 12 months?
Dr. Martens Plc lowest stock price was €0.66 and its highest was €1.11 in the past 12 months.
What is Dr. Martens Plc’s market cap?
Dr. Martens Plc’s market cap is €789.64M.
When is Dr. Martens Plc’s upcoming earnings report date?
Dr. Martens Plc’s upcoming earnings report date is Nov 19, 2026 which is in 165 days.
How were Dr. Martens Plc’s earnings last quarter?
Dr. Martens Plc released its earnings results on May 19, 2026. The company reported €0.049 earnings per share for the quarter, missing the consensus estimate of €0.051 by -€0.002.
Is Dr. Martens Plc overvalued?
According to Wall Street analysts Dr. Martens Plc’s price is currently Undervalued.
Does Dr. Martens Plc pay dividends?
Dr. Martens Plc does not currently pay dividends.
What is Dr. Martens Plc’s EPS estimate?
Dr. Martens Plc’s EPS estimate is <0.01.
How many shares outstanding does Dr. Martens Plc have?
Dr. Martens Plc has 967,943,540 shares outstanding.
What happened to Dr. Martens Plc’s price movement after its last earnings report?
Dr. Martens Plc reported an EPS of €0.049 in its last earnings report, missing expectations of €0.051. Following the earnings report the stock price went up 3.731%.
Which hedge fund is a major shareholder of Dr. Martens Plc?
Currently, no hedge funds are holding shares in DE:3U2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Martens Plc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€1.14 (58.16% Upside)
€1.14 (58.16% Upside)
Insider Transactions
Sold Shares
Worth €155.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.87%
12-Months-Change
Fundamentals
Return on Equity
6.89%
Trailing 12-Months
Asset Growth
-1.40%
Trailing 12-Months
Company Description
Dr. Martens Plc
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Its product segments include originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.
3U2 Stock 12 Month Forecast
Average Price Target
€1.14
▲(58.16% Upside)
Technical Analysis
Options Prices
Currently, No data available
---